home / stock / addxf / addxf quote
Last: | $0.99 |
---|---|
Change Percent: | 0.0% |
Open: | $0.99 |
Close: | $0.99 |
High: | $0.99 |
Low: | $0.99 |
Volume: | 100 |
Last Trade Date Time: | 02/03/2022 04:53:25 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.99 | $0.99 | $0.99 | $0.99 | $0.99 | 100 | 02-03-2022 |
$1.56 | $1.56 | $1.56 | $1.56 | $1.56 | 5,000 | 07-26-2021 |
$1.65 | $1.65 | $1.65 | $1.65 | $1.65 | 4,012 | 06-03-2021 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $2.05 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $2.05 | $2.05 | $2.05 | $2.05 | 300 | 01-30-2020 |
$ | $N/A | $1.91 | $N/A | $N/A | 0 | 01-29-2020 |
$ | $N/A | $1.91 | $N/A | $N/A | 0 | 01-28-2020 |
$ | $N/A | $1.91 | $N/A | $N/A | 0 | 01-27-2020 |
$ | $N/A | $1.91 | $N/A | $N/A | 0 | 01-24-2020 |
$ | $N/A | $1.91 | $N/A | $N/A | 0 | 01-23-2020 |
$ | $N/A | $1.91 | $N/A | $N/A | 0 | 01-22-2020 |
$ | $N/A | $1.91 | $N/A | $N/A | 0 | 01-21-2020 |
News, Short Squeeze, Breakout and More Instantly...
Addex Pharms Ltd Ord Company Name:
ADDXF Stock Symbol:
OTCMKTS Market:
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, t...
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April ...
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing ...